Payment & Shipping Terms:
|Synonyms:||2-AMINO-N-(2-CHLORO-6-METHYLPHENYL)THIAZOLE-5-CARBOXAMIDE;2-AMino-N-(2-chloro-6-Methylphenyl)thiazole-5-carb;2-aMino-N-(2-chloro-6-Methylphenyl)-1,3-thiazole-5-carboxaMide;dasatinib InterMediate;Dasatinib IMpurity 2;2-AMino-N-(2-chloro-6-Methylphenyl)thiaz||Application:||Intermediate Of API Dasatinib|
active pharmaceuticals ingredients,
active pharma ingredients
302964-24-5 Dasatinib Intermediate Pharmaceutical Active Ingredients
2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide is one kind of intermediate of dasatinib.
|Synonyms:||2-AMINO-N-(2-CHLORO-6-METHYLPHENYL)THIAZOLE-5-CARBOXAMIDE;2-AMino-N-(2-chloro-6-Methylphenyl)thiazole-5-carb;2-aMino-N-(2-chloro-6-Methylphenyl)-1,3-thiazole-5-carboxaMide;dasatinib interMediate;Dasatinib IMpurity 2;2-AMino-N-(2-chloro-6-Methylphenyl)thiazole-5-carboxiMide);2-Amino-5-[(2-chloro-6-methylphenyl)carbamoyl]-1,3-thiazole, 2-Amino-5-[(6-chloro-o-tolyl)carbamoyl]-1,3-thiazole|
|Product Categories:||Dasatinib;API intermediates|
Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.
|Appearance||Off- white to pale yellow powder||Off-white powder|
|Identification||IR absorption spectrum of sample should be consistent with spectrum of standard||Conforms|
|Water||No more than0.70%||0.50%|
|Residue on ignition||No more than 0.50%||0.17%|
Thuourea no more than 0.07%
Individual impurity no more than 0.20%
Total impurities no more than 0.50%%
|Assay||98.0%-102.0% (On anhydrous basis)||99.7%|
In a Phase I dose escalation study published in June 2006, dasatinib was tested in patients who were resistant to or who could not tolerate imatinib. Complete hematological responses were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL.
1. Are you a manufacturer ?
Yes, We manufacture bulk products in our factory located in Jiayu, Hubei, and produce small quantity and customer synthesis products in our lab located in Wuhan. But we also do some trading business
2. How to confirm the product quality before placing orders ?
a. We will offer you our products specification standard to you, and we test every batch of our product by HPLC, UV, GC and TLC and etc. We also cooperate with independent third party lab such as SGS,PONY etc.
b. Free samples of some products can be sent, only need to pay the shipping cost or arrange a courier to us and take the samples.
c. Send us your products specifications and requests, we will produce for you.
3. How to make order & payment ?
a. Proforma invoice will be sent after your confirmation of the order, or You can order from Alibaba ESCOW(SECURE PAYMENT), Trade Assurance
b. We can accept payment by T/T, Western Union, Escrow, ,Trade Assurance, L/C.
4. How to pack and storage ?
a. Packing: 1kg/Aluminum foil bag with Carton outside.
25kg/Fiber drum with double PE bags inside.
b. Storage: Store in cool & dry place, keep away from strong light and heat.
5. How to ship and delivery ?
a. Transit could be DHL,UPS,TNT, FEDEX, EMS. For mass orders, it will be delivered by air or sea.
b. Depending on your location,
For small order, please expect 5-7 days by DHL,UPS,TNT, FEDEX, EMS.
For mass order, please allow 5-8 days by Air, 20-35 days by Sea.
6. Our return service policy
We offer an unconditional,full money back guarantee. if you are not 100% satisfied with our products ,return all goods back to us within 60 day and we will fully refund your money. No questions asked.
Contact Person: Ms. du
Tel: 86 13277095342